NSE: CIPLA | BSE: 500087

Mid-range Performer

Download real time

1515.50 2.40 (0.16%)

113.4K NSE+BSE Volume

NSE 07 Oct, 2025 10:43 AM (IST)

122,416.9

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Cipla Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for CIPLA, BSE:500087 Cipla Ltd.

Cipla Ltd.

15 May 2023

1515.50

0.16%

Result Update:Cipla

Buy: Cipla Ltd.

Target

Axis Direct

Company Outlook & Guidance: gAdvair and gAbraxane may add revenue in FY25E despite current regulatory challenges. gSynbicort is to be launched in Q4FY24 and the company has planned to launch three more peptides in the next year (size $30-50 Mn).

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

13 May 2023

1515.50

0.16%

Cipla

Buy: Cipla Ltd.

Target

ICICI Direct

Cipla Ltd. is trading above its 200 day SMA of 1496.4

Cipla Ltd.

13 May 2023

1515.50

0.16%

Cipla (BUY): Key launches at least a year away

Buy: Cipla Ltd.

Target

BOB Capital Markets Ltd.

Q4 EBITDA/PAT grew 57%/45% YoY but missed consensus by 5%/30% on higher R&D spend, field force expansion and other costs

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

01 Mar 2023

1515.50

0.16%

CIPLA LTD.

Buy: Cipla Ltd.

Target

Prabhudas Lilladhar

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

28 Feb 2023

1515.50

0.16%

Regulatory risks on the rise

Neutral: Cipla Ltd.

Target

Motilal Oswal

Cipla Ltd. is trading above its 200 day SMA of 1496.4

Cipla Ltd.

27 Jan 2023

1515.50

0.16%

Cipla

Buy: Cipla Ltd.

Target

ICICI Direct

Cipla Ltd. is trading above its 200 day SMA of 1496.4

Cipla Ltd.

27 Jan 2023

1515.50

0.16%

US drives growth; complex launches remain key

Hold: Cipla Ltd.

Target

ICICI Securities Limited

Cipla’s Q3FY23 performance was largely in line with our estimates. Revenue grew 6% YoY to Rs58.1bn (I-Sec: Rs.58.8bn) driven by a strong uptick in US revenue (US$195mn, +8.9% QoQ), which partially benefitted from continued traction in Revlimid and a strong seasonal quarter of its key products.

Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.

Cipla Ltd.

27 Jan 2023

1515.50

0.16%

Strategy: Technical Result Preview

Strategy Note: Cipla Ltd.

Bonanza

Since the last result, the prices have corrected till Q1: 22-23 result range and Pivot level of 1,040. Till Cipla sustains above these levels chance of bouncing back is very high. One can start buying in Cipla above 20EMA that is 1,078.

Cipla Ltd. is trading above its 200 day SMA of 1496.4

Is Cipla Ltd. worth buying?

625 Votes:

Buy 75.84%

Sell 13.92%

Hold 10.24%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf